NASDAQ:SWKH SWK Q4 2024 Earnings Report $14.60 -0.17 (-1.15%) Closing price 04:00 PM EasternExtended Trading$14.60 0.00 (-0.03%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings History SWK EPS ResultsActual EPS$0.54Consensus EPS $0.94Beat/MissMissed by -$0.40One Year Ago EPSN/ASWK Revenue ResultsActual Revenue$12.36 millionExpected Revenue$9.70 millionBeat/MissBeat by +$2.66 millionYoY Revenue GrowthN/ASWK Announcement DetailsQuarterQ4 2024Date3/19/2025TimeAfter Market ClosesConference Call DateThursday, March 20, 2025Conference Call Time10:00AM ETUpcoming EarningsSWK's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 10:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by SWK Q4 2024 Earnings Call TranscriptProvided by QuartrMarch 20, 2025 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:00Greetings. Welcome to the SWK Holdings Fourth Quarter twenty twenty four Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. Operator00:00:20I will now turn the conference over to your host, Susan Zhu, Investor Relations. You may begin. Speaker 100:00:27Thank you. Good morning, everyone, and thank you for joining SWK Holdings' fourth quarter twenty twenty four financial and corporate results call. Yesterday, SWK Holdings issued a press release detailing its financial results for the three months ended 12/31/2024. The press release can be found in the Investor Relations section of swkhold.com under News Releases. Before beginning today's call, I would like to make the following statement regarding forward looking statements. Speaker 100:00:59Today, we will make certain forward looking statements about future expectations, plans, events and circumstances, including statements about our strategy, future operations and our expectations regarding our capital allocation and cash resources. These statements are based on our current expectations and you should not place undue reliance on these statements. Actual results may differ materially due to our risks and uncertainties, including those detailed in the Risks and Uncertainties Factor section of SWK Holdings ten K filed with the SEC and other filings we make with the SEC from time to time. SWK Holdings disclaims any obligation to update information contained in these forward looking statements whether as a result of new information, future events or otherwise. Joining me from SWK Holdings on today's call is Jody Staggs, President and CEO and Adam Reis, CFO, who will provide an update on SWK fourth quarter twenty twenty four corporate and financial results. Speaker 100:02:07Jody, go ahead. Speaker 200:02:09Thank you, Susan, and thanks everyone for joining our fourth quarter conference call. We are pleased with SWK's fourth quarter performance and the company enters 2025 on solid footing. Our fourth quarter was highlighted by solid financial performance, including $8,200,000 of finance segment net income, improvement in the portfolio's credit quality and $44,000,000 of capital deployed into yielding finance receivables to life science companies. Our non GAAP tangible financing book value per share increased 8% year over year to $21.15 and with share trading at a discount to book and given our excess capital, we have been active purchasers of our shares and having repurchased approximately 100,000 shares for $1,600,000 since 09/30/2024. During the fourth quarter, we closed an up to $8,000,000 senior secured term loan to Triple Ring Technologies, upsized the loan to $30,000,000 and advanced a cumulative $10,600,000 to four performing borrowers. Speaker 200:03:08In January, we closed an up to $15,000,000 term loan with Impedimed with $10,000,000 advanced at close. These are all core SWK financings to commercial stage life science companies. Each is either public and has demonstrated the ability to raise capital or private with a supportive sponsor. Since we last spoke, three STVK financial receivables were repaid at premiums to the GAAP carrying value. In December, VERU made a $4,200,000 payment to fully satisfy the FC2 royalty. Speaker 200:03:39The FC2 royalty generated a 45% IRR and a 2.7 X MOIC. In December, Molecularite made a final payment totaling $12,200,000 to repay its term loan to SWK. The Molecularite term loan generated a 20% IRR and a 1.6 MOIC. SWK continues to hold equity in Molecularite, which is carried at zero on our books. In March, ANI Pharma made a $17,250,000 payment to exercise an option to buy out the ILUVIEN royalty. Speaker 200:04:10The ILUVIEN royalty generated a 20% IRR and a 1.8x MOIC. At 12/31/2024, we had $13,800,000 of gross finance receivables on non accrual. The non accrual receivables have a 15% CECL reserve thus our net non accrual totaled $11,700,000 This morning, we announced the signing of a transaction to sell our remaining performing royalty portfolio for $34,000,000 The deal is expected to close in approximately two weeks. In combination with the ILUVIEN buyout, the $51,300,000 of proceeds from the two monetization transactions is approximately $1,000,000,000 more than the carrying value at 12/31/2024. Upon closing of the transaction, we also expect to close out a Japanese yen hedge, which will free up an additional $4,500,000 of cash. Speaker 200:05:04Pro form a for these changes, as well as a $3,000,000 principal repayment from 4Web in the first quarter of twenty twenty five and using the twelvethirty onetwenty twenty four balances, our go forward gross portfolio consists of approximately $218,000,000 of performing loans, $14,000,000 of non accruals and approximately $5,000,000 of equity spend warrants. Our fourth quarter twenty twenty four portfolio effective yield was 15.5%. The effective yield is a yield assuming all financial receivables pay as modeled. This figure is not adjusted for the post quarter changes, but should be in the neighborhood of the go forward portfolio yield, even considering the royalty sale. Finally, as of yesterday, our cash totaled over $30,000,000 and we have no borrowings under our revolver. Speaker 200:05:54Assuming closing of the final royalty transaction and release of the FX hedge, our gross cash will total nearly $70,000,000 We anticipate the Board will declare a dividend on the closing of the final royalty transaction. Turning to our Entera CDMO division, which has been rebranded as Mod3 Pharma to signify its transformation into a pure play CDMO business. We are pleased with MOD3's twenty twenty four results as segment division revenue totaled $3,600,000 tripling from $1,200,000 in 2023. We expect continued growth in 2025 and the team is focused on positioning the business for unsubsidized profitability by year end. We are in regular contact with our strategic partner and believe they are pleased with MOD3's performance. Speaker 200:06:40With that, I will turn the call to our CFO, Adam Rice to review the quarter's financial results. Speaker 300:06:48Thank you, Jody, and good morning, everyone. Yesterday, we reported earnings for the fourth quarter of twenty twenty four. We reported GAAP pre tax net income of $8,600,000 or $0.7 per diluted share. Our reported fourth quarter twenty twenty four net income of $5,900,000 after income tax expense of $2,700,000 included a $1,100,000 increase in finance receivable segment revenue and a $1,300,000 increase in Pharmaceutical Development segment revenue. The $1,100,000 increase in revenue or in year over year finance receivable segment revenue was primarily due to a $2,300,000 increase in interest and fees earned on newly funded loans and royalties. Speaker 300:07:35The accelerated fees on early payoffs and accelerated fees on early payoffs. The increase in finance receivable segment revenue was partially offset by $900,000 as a result of two investments entering non accrual status this year. As of 12/31/2024, our GAAP book value per share was $23.45 a 5% increase compared to $22.33 as of 12/31/2023. Additionally, non GAAP tangible finance book value per share totaled $21.15 as of 12/31/2024, and 8.3% increase compared to $19.53 as of 12/31/2023. Overall operating expenses, which overall operating expenses, which include interest expense, pharmaceutical manufacturing, research and development expense, general and administrative expense and provision for credit losses were $6,600,000 during fourth quarter twenty twenty four compared to $6,800,000 in fourth quarter twenty twenty three. Speaker 300:08:44Mod three operating expenses were $1,600,000 in fourth quarter twenty twenty four compared to $1,800,000 in fourth quarter twenty twenty three. And finance receivable segment operating expenses were $5,300,000 in fourth quarter twenty twenty four compared to $5,600,000 in fourth quarter twenty twenty three. The finance receivable operating segment expenses further breakdown for fourth quarter twenty twenty four to general and administrative expenses of 2,100,000 provision for credit losses of $2,000,000 and interest expense of $1,200,000 and for fourth quarter twenty twenty three general and administrative expenses expenses of $2,100,000 provision for credit losses of $2,400,000 and interest expense of $1,100,000 The decrease in finance receivable segment operating expenses was mainly due to a $400,000 decrease in provision for credit losses. The decrease in provision for credit losses is most notably attributed to the strategic exit of three non accrual investments during the quarter. Turning to our share repurchase program, we bought back roughly 50,000 shares at a total cost of $800,000 during the quarter. Speaker 300:10:01Since quarter close, we have repurchased an additional 47,000 shares for a total cost of $800,000 Lastly, for financial reporting purposes, we have transitioned the Montserrat segment to held for sale as of 12/31/2024. The transition to held for sale status was based on criteria set forth in GAAP accounting guidance and is related to the option purchase agreement entered into between Modderie and a strategic partner effective 01/01/2024. With that, I'll turn it back over to Jody. Speaker 200:10:37Thank you, Adam. We entered 2025 with a healthy loan portfolio yielding in the mid teens as well as $30,000,000 of gross cash. The sale of our remaining performing royalty portfolio and close out of the FX hedge will add an additional $39,000,000 of cash to our balance sheet and we anticipate declaring a dividend on the closing of the final royalty transaction. Our MOD III CDMO division is self sufficient and working with our strategic partner to address the sizable need for Phase one and Phase two nasal CDMO services. With that, let's open the call to questions. Operator00:11:12Absolutely. At this time, we will be conducting a question and answer session. The first question comes from Scott Jensen, private investor. Please proceed. Speaker 400:11:47Hi, good morning, Jody and team. Congratulations on Speaker 500:11:52so much progress since we last spoke. Speaker 400:11:54I guess I got a couple of questions for you. When you're thinking about a dividend, since it's such a large pile of cash, are you thinking about ongoing dividend or a special dividend returning some of that cash, that cash pile to shareholders? Speaker 200:12:11I would yes, Scott, thanks. So the Board is still considering our options. I would anticipate initially a one time special dividend. That doesn't mean that there might not be additional special dividends in the future. But at this time, I don't anticipate a recurring dividend. Speaker 400:12:32Yes. Love it. That's what I would hope for as well. Second, as far as the buyback, where are you on the current buyback? And then again, is that going to be something the Board is going to consider about renewing or increasing the buyback? Speaker 200:12:49Yes. And Adam, if you have the email pulled up, I might from Courtney, I might have you look and check how much room we have, but we do have room enough room on our buyback. It's been interesting trying to navigate this with our blackout period. So once we go into the blackout period, the algorithm takes over and we don't really have control over how many shares are repurchased. When we're not in the blackout period, we can direct it and be more aggressive or less aggressive. Speaker 200:13:20So I would say we're still active repurchasing of our shares. We think particularly with the news we announced today, shares are trading at a 20% discount. That's an attractive use of capital. So we'll continue to do that. We should be out of the blackout period when we report first quarter roughly May 15 in that ballpark. Speaker 200:13:43And the program will expire. I think it expires roughly that date. I don't we have not discussed it, but I think the Board views the buyback as an attractive use of capital. And I would expect assuming everything else is equal that the Board would strongly consider reauthorizing the program for another year. Speaker 400:14:05Excellent. Thank you. And I just also want to say congratulations on all those workouts, BioLase, etcetera. Those were excellent in cleaning it up. Speaker 200:14:18Thank you, Scott. Speaker 400:14:20I will get out of queue and see if somebody else, but keep up the good work and thank you again and love reading the progress. Speaker 200:14:28Thank you. Appreciate the support. Operator00:14:56Okay. We have no further questions in the queue. I would like to turn the floor back to Jody for any closing remarks. Speaker 200:15:04Thanks, John. Thank you for joining us today and for your continued support of SWK. We hope everyone has a great day. Thanks. Operator00:15:13This concludes today's conference and you may disconnect your lines at this time. Thank you for your participation.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallSWK Q4 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Annual report(10-K) SWK Earnings HeadlinesSWK Holdings Corporation Announces Financial Results for Fourth Quarter 2024 - The Globe and MailMarch 21, 2025 | theglobeandmail.comSWK Holdings Corporation (SWKH) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 25, 2025 | Paradigm Press (Ad)SWK Holdings Corp.: SWK Holdings Corporation Announces Financial Results for Fourth Quarter 2024March 20, 2025 | finanznachrichten.deSWK Holdings Corp.: SWK Holdings Announces Monetization of Royalty PortfolioMarch 20, 2025 | finanznachrichten.deSWK Holdings' (NASDAQ:SWKH) investors will be pleased with their notable 66% return over the last five yearsMarch 17, 2025 | finance.yahoo.comSee More SWK Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SWK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SWK and other key companies, straight to your email. Email Address About SWKSWK (NASDAQ:SWKH), offers specialty finance and asset management services in the United States. It operates in two segments, Finance Receivables and Pharmaceutical Development. The Finance Receivables segment provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. This segment also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The Pharmaceutical Development segment provides customers pharmaceutical development, formulation, and manufacturing services, as well as formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence platform. It also offers intellectual property licensing business. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was incorporated in 1996 and is headquartered in Dallas, Texas.View SWK ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Tesla Earnings Miss, But Musk Refocuses and Bulls ReactQualcomm’s Range Narrows Ahead of Earnings as Bulls Step In Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Booking (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:00Greetings. Welcome to the SWK Holdings Fourth Quarter twenty twenty four Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. Operator00:00:20I will now turn the conference over to your host, Susan Zhu, Investor Relations. You may begin. Speaker 100:00:27Thank you. Good morning, everyone, and thank you for joining SWK Holdings' fourth quarter twenty twenty four financial and corporate results call. Yesterday, SWK Holdings issued a press release detailing its financial results for the three months ended 12/31/2024. The press release can be found in the Investor Relations section of swkhold.com under News Releases. Before beginning today's call, I would like to make the following statement regarding forward looking statements. Speaker 100:00:59Today, we will make certain forward looking statements about future expectations, plans, events and circumstances, including statements about our strategy, future operations and our expectations regarding our capital allocation and cash resources. These statements are based on our current expectations and you should not place undue reliance on these statements. Actual results may differ materially due to our risks and uncertainties, including those detailed in the Risks and Uncertainties Factor section of SWK Holdings ten K filed with the SEC and other filings we make with the SEC from time to time. SWK Holdings disclaims any obligation to update information contained in these forward looking statements whether as a result of new information, future events or otherwise. Joining me from SWK Holdings on today's call is Jody Staggs, President and CEO and Adam Reis, CFO, who will provide an update on SWK fourth quarter twenty twenty four corporate and financial results. Speaker 100:02:07Jody, go ahead. Speaker 200:02:09Thank you, Susan, and thanks everyone for joining our fourth quarter conference call. We are pleased with SWK's fourth quarter performance and the company enters 2025 on solid footing. Our fourth quarter was highlighted by solid financial performance, including $8,200,000 of finance segment net income, improvement in the portfolio's credit quality and $44,000,000 of capital deployed into yielding finance receivables to life science companies. Our non GAAP tangible financing book value per share increased 8% year over year to $21.15 and with share trading at a discount to book and given our excess capital, we have been active purchasers of our shares and having repurchased approximately 100,000 shares for $1,600,000 since 09/30/2024. During the fourth quarter, we closed an up to $8,000,000 senior secured term loan to Triple Ring Technologies, upsized the loan to $30,000,000 and advanced a cumulative $10,600,000 to four performing borrowers. Speaker 200:03:08In January, we closed an up to $15,000,000 term loan with Impedimed with $10,000,000 advanced at close. These are all core SWK financings to commercial stage life science companies. Each is either public and has demonstrated the ability to raise capital or private with a supportive sponsor. Since we last spoke, three STVK financial receivables were repaid at premiums to the GAAP carrying value. In December, VERU made a $4,200,000 payment to fully satisfy the FC2 royalty. Speaker 200:03:39The FC2 royalty generated a 45% IRR and a 2.7 X MOIC. In December, Molecularite made a final payment totaling $12,200,000 to repay its term loan to SWK. The Molecularite term loan generated a 20% IRR and a 1.6 MOIC. SWK continues to hold equity in Molecularite, which is carried at zero on our books. In March, ANI Pharma made a $17,250,000 payment to exercise an option to buy out the ILUVIEN royalty. Speaker 200:04:10The ILUVIEN royalty generated a 20% IRR and a 1.8x MOIC. At 12/31/2024, we had $13,800,000 of gross finance receivables on non accrual. The non accrual receivables have a 15% CECL reserve thus our net non accrual totaled $11,700,000 This morning, we announced the signing of a transaction to sell our remaining performing royalty portfolio for $34,000,000 The deal is expected to close in approximately two weeks. In combination with the ILUVIEN buyout, the $51,300,000 of proceeds from the two monetization transactions is approximately $1,000,000,000 more than the carrying value at 12/31/2024. Upon closing of the transaction, we also expect to close out a Japanese yen hedge, which will free up an additional $4,500,000 of cash. Speaker 200:05:04Pro form a for these changes, as well as a $3,000,000 principal repayment from 4Web in the first quarter of twenty twenty five and using the twelvethirty onetwenty twenty four balances, our go forward gross portfolio consists of approximately $218,000,000 of performing loans, $14,000,000 of non accruals and approximately $5,000,000 of equity spend warrants. Our fourth quarter twenty twenty four portfolio effective yield was 15.5%. The effective yield is a yield assuming all financial receivables pay as modeled. This figure is not adjusted for the post quarter changes, but should be in the neighborhood of the go forward portfolio yield, even considering the royalty sale. Finally, as of yesterday, our cash totaled over $30,000,000 and we have no borrowings under our revolver. Speaker 200:05:54Assuming closing of the final royalty transaction and release of the FX hedge, our gross cash will total nearly $70,000,000 We anticipate the Board will declare a dividend on the closing of the final royalty transaction. Turning to our Entera CDMO division, which has been rebranded as Mod3 Pharma to signify its transformation into a pure play CDMO business. We are pleased with MOD3's twenty twenty four results as segment division revenue totaled $3,600,000 tripling from $1,200,000 in 2023. We expect continued growth in 2025 and the team is focused on positioning the business for unsubsidized profitability by year end. We are in regular contact with our strategic partner and believe they are pleased with MOD3's performance. Speaker 200:06:40With that, I will turn the call to our CFO, Adam Rice to review the quarter's financial results. Speaker 300:06:48Thank you, Jody, and good morning, everyone. Yesterday, we reported earnings for the fourth quarter of twenty twenty four. We reported GAAP pre tax net income of $8,600,000 or $0.7 per diluted share. Our reported fourth quarter twenty twenty four net income of $5,900,000 after income tax expense of $2,700,000 included a $1,100,000 increase in finance receivable segment revenue and a $1,300,000 increase in Pharmaceutical Development segment revenue. The $1,100,000 increase in revenue or in year over year finance receivable segment revenue was primarily due to a $2,300,000 increase in interest and fees earned on newly funded loans and royalties. Speaker 300:07:35The accelerated fees on early payoffs and accelerated fees on early payoffs. The increase in finance receivable segment revenue was partially offset by $900,000 as a result of two investments entering non accrual status this year. As of 12/31/2024, our GAAP book value per share was $23.45 a 5% increase compared to $22.33 as of 12/31/2023. Additionally, non GAAP tangible finance book value per share totaled $21.15 as of 12/31/2024, and 8.3% increase compared to $19.53 as of 12/31/2023. Overall operating expenses, which overall operating expenses, which include interest expense, pharmaceutical manufacturing, research and development expense, general and administrative expense and provision for credit losses were $6,600,000 during fourth quarter twenty twenty four compared to $6,800,000 in fourth quarter twenty twenty three. Speaker 300:08:44Mod three operating expenses were $1,600,000 in fourth quarter twenty twenty four compared to $1,800,000 in fourth quarter twenty twenty three. And finance receivable segment operating expenses were $5,300,000 in fourth quarter twenty twenty four compared to $5,600,000 in fourth quarter twenty twenty three. The finance receivable operating segment expenses further breakdown for fourth quarter twenty twenty four to general and administrative expenses of 2,100,000 provision for credit losses of $2,000,000 and interest expense of $1,200,000 and for fourth quarter twenty twenty three general and administrative expenses expenses of $2,100,000 provision for credit losses of $2,400,000 and interest expense of $1,100,000 The decrease in finance receivable segment operating expenses was mainly due to a $400,000 decrease in provision for credit losses. The decrease in provision for credit losses is most notably attributed to the strategic exit of three non accrual investments during the quarter. Turning to our share repurchase program, we bought back roughly 50,000 shares at a total cost of $800,000 during the quarter. Speaker 300:10:01Since quarter close, we have repurchased an additional 47,000 shares for a total cost of $800,000 Lastly, for financial reporting purposes, we have transitioned the Montserrat segment to held for sale as of 12/31/2024. The transition to held for sale status was based on criteria set forth in GAAP accounting guidance and is related to the option purchase agreement entered into between Modderie and a strategic partner effective 01/01/2024. With that, I'll turn it back over to Jody. Speaker 200:10:37Thank you, Adam. We entered 2025 with a healthy loan portfolio yielding in the mid teens as well as $30,000,000 of gross cash. The sale of our remaining performing royalty portfolio and close out of the FX hedge will add an additional $39,000,000 of cash to our balance sheet and we anticipate declaring a dividend on the closing of the final royalty transaction. Our MOD III CDMO division is self sufficient and working with our strategic partner to address the sizable need for Phase one and Phase two nasal CDMO services. With that, let's open the call to questions. Operator00:11:12Absolutely. At this time, we will be conducting a question and answer session. The first question comes from Scott Jensen, private investor. Please proceed. Speaker 400:11:47Hi, good morning, Jody and team. Congratulations on Speaker 500:11:52so much progress since we last spoke. Speaker 400:11:54I guess I got a couple of questions for you. When you're thinking about a dividend, since it's such a large pile of cash, are you thinking about ongoing dividend or a special dividend returning some of that cash, that cash pile to shareholders? Speaker 200:12:11I would yes, Scott, thanks. So the Board is still considering our options. I would anticipate initially a one time special dividend. That doesn't mean that there might not be additional special dividends in the future. But at this time, I don't anticipate a recurring dividend. Speaker 400:12:32Yes. Love it. That's what I would hope for as well. Second, as far as the buyback, where are you on the current buyback? And then again, is that going to be something the Board is going to consider about renewing or increasing the buyback? Speaker 200:12:49Yes. And Adam, if you have the email pulled up, I might from Courtney, I might have you look and check how much room we have, but we do have room enough room on our buyback. It's been interesting trying to navigate this with our blackout period. So once we go into the blackout period, the algorithm takes over and we don't really have control over how many shares are repurchased. When we're not in the blackout period, we can direct it and be more aggressive or less aggressive. Speaker 200:13:20So I would say we're still active repurchasing of our shares. We think particularly with the news we announced today, shares are trading at a 20% discount. That's an attractive use of capital. So we'll continue to do that. We should be out of the blackout period when we report first quarter roughly May 15 in that ballpark. Speaker 200:13:43And the program will expire. I think it expires roughly that date. I don't we have not discussed it, but I think the Board views the buyback as an attractive use of capital. And I would expect assuming everything else is equal that the Board would strongly consider reauthorizing the program for another year. Speaker 400:14:05Excellent. Thank you. And I just also want to say congratulations on all those workouts, BioLase, etcetera. Those were excellent in cleaning it up. Speaker 200:14:18Thank you, Scott. Speaker 400:14:20I will get out of queue and see if somebody else, but keep up the good work and thank you again and love reading the progress. Speaker 200:14:28Thank you. Appreciate the support. Operator00:14:56Okay. We have no further questions in the queue. I would like to turn the floor back to Jody for any closing remarks. Speaker 200:15:04Thanks, John. Thank you for joining us today and for your continued support of SWK. We hope everyone has a great day. Thanks. Operator00:15:13This concludes today's conference and you may disconnect your lines at this time. Thank you for your participation.Read morePowered by